Temozolomide in the treatment of solid tumours: current results and rationale for dosing/scheduling.
This review examines the current evidence for the use of temozolomide in the treatment of solid tumours. The possible molecular and clinical advantages of temozolomide are identified and the molecular mechanism of temozolomide resistance is explored. Attempts to maximise efficacy have led to manipulation of both dosage and drug scheduling and the evidence for the various strategies is reviewed. Finally, the potential role of combination therapy is considered.
Payne
M J
MJ
The Churchill Hospital, CRUK Medical Oncology Unit, Oxford Radcliffe Hospitals Trust, Headington, Oxford OX37LJ, UK.
Pratap
S E
SE
Middleton
M R
MR
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D004260:DNA Repair / Q000187:drug effects; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology; D004334:Drug Administration Schedule; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D000077204:Temozolomide; D016896:Treatment Outcome
D003606:Dacarbazine; D000077204:Temozolomide